MS BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: BNTX Forum: Aktien User: Thekla
101,87 USD
+2,16 %+2,15
19. Nov, 02:00:00 Uhr,
Nasdaq
Kommentare 246.113
Marley16,
06.06.2024 15:33 Uhr
1
Moin
🚢🌊🚢🌊💯🏖🍀
hotzenplotz5,
06.06.2024 15:31 Uhr
0
Börse .....
Thekla,
06.06.2024 15:30 Uhr
0
🕞NASDAQ START🕞
🔔9️⃣4️⃣,3️⃣5️⃣🔔
Fan1982,
06.06.2024 15:17 Uhr
1
🙋♂️🇺🇸👀🫡
Marley16,
06.06.2024 14:58 Uhr
0
Markus Koch Opening Bell
https://www.youtube.com/live/sYS9g5gEvNU?si=ovcWged0kQv6OkIO
Kempti2000,
06.06.2024 14:56 Uhr
2
Hallo meine Lieben.
Ausgugg ✅
Auf gehts BioNTech 🍀🍀🍀
Thekla,
06.06.2024 14:55 Uhr
1
🕞⛴️🌍🕊🌊⛴️ 🕞👮🏼♀️👋
Leitzins⬇️
BioNTech ⬆️
Jo -Jo Tag ⬆️ ⬇️🤔
hotzenplotz5,
06.06.2024 14:36 Uhr
0
Vogelgrippe? lol
Tommy311073,
06.06.2024 14:26 Uhr
0
$MRNA Moderna's mRNA-3705 selected by FDA for START pilot program Moderna announced that the U.S. Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia due to methylmalonic-CoA mutase deficiency. The START pilot program was initiated by the U.S. FDA in September 2023 to accelerate the development of novel treatments addressing unmet medical needs in rare diseases, with an initial selection of up to seven novel treatments, three by the Center for Drug Evaluation and Research and four by the Center for Biologics Evaluation and Research. The milestone-driven initiative is intended to help the progression to pivotal clinical studies or pre-BLA/NDA meeting stages by enhancing communications between manufacturers and the U.S. FDA. Selected manufacturers will benefit from rapid, ad-hoc U.S. FDA interactions to support clinical development, such as study design, patient population, and statistical methods, beyond standard formal meetings. The program is designed to generate high-quality, reliable data to support marketing approvals, ensuring promising treatments advance efficiently through regulatory milestones. mRNA-3705 is being investigated in a Phase 1/2 study, called the "Landmark study," an adaptive, open-label study designed to evaluate the safety and tolerability of the investigational therapeutic administered via intravenous infusion in patients one year and older with isolated MMA due to methylmalonyl-CoA mutase deficiency.
Kempti2000,
06.06.2024 14:22 Uhr
0
EZB senkt Leitzins um 0,25 Prozent
Fan1982,
06.06.2024 14:12 Uhr
0
🙋♂️👀
Mehr zu diesem Wert
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | Trading- und Aktien-Chat | ||
2 | Super Micro Computer Hauptdiskussion | +15,93 % | |
3 | SAYONA MINING LTD Hauptdiskussion | +5,00 % | |
4 | für alle, die es ehrlich meinen beim Traden. | ||
5 | XIAOMI CORP. CL.B Hauptdiskussion | +6,72 % | |
6 | ROCK TECH LITHIUM Hauptdiskussion | +0,51 % | |
7 | Nio für normale Kommunikation | +3,78 % | |
8 | BP Hauptdiskussion | ±0,00 % | |
9 | Cypher | ±0,00 % | |
10 | Aktien und Saunaclub alla Luci | Alle Diskussionen |
Aktien
|
Thema | ||
---|---|---|---|
1 | Super Micro Computer Hauptdiskussion | +15,93 % | |
2 | SAYONA MINING LTD Hauptdiskussion | +5,00 % | |
3 | XIAOMI CORP. CL.B Hauptdiskussion | +6,72 % | |
4 | ROCK TECH LITHIUM Hauptdiskussion | +0,51 % | |
5 | Nio für normale Kommunikation | +3,78 % | |
6 | BP Hauptdiskussion | ±0,00 % | |
7 | Cypher | ±0,00 % | |
8 | ALTECH CHEMICALS Hauptdiskussion | -24,24 % | |
9 | Samsung SDI eine der innovativsten Globalplayer in Sachen in Sachen Energiespeicher. | +4,51 % | |
10 | Vulcan Energy Resources Hauptdiskussion | +8,24 % | Alle Diskussionen |